ONC vs PEN
BeOne Medicines AG vs Penumbra, Inc. — AI-powered side-by-side comparison
ONC
BeOne Medicines AG
64
Buy
VS
PEN
Penumbra, Inc.
67
Buy
| Metric | ONC | PEN |
|---|
| AI Score |
64
|
67
|
| Price |
$359.20
|
$326.07
|
| P/E Ratio |
29.70×
|
79.78×
|
| ROE |
6.6%
|
12.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
87.8%
|
67.8%
|
| Debt / Equity |
0.22×
|
0.14×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
84.1
|
79.6
|
| Beta |
0.5
|
0.701
|
| Expected Upside |
—
|
+6.3%
|
AI Committee View
Current Innellis committee reasoning for ONC versus PEN.
PEN leads by 3 points.
PEN scores 67/100 (Buy) versus ONC at 64/100 (Buy).
ONC Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 36.2% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 86.0 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 36.2% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 86.0 is expensive by classic value standards — Value
- Price-to-book of 8.7x prices in significant intangible value — Value
- RSI at 84 is in overbought territory — Technical
PEN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 consecutive earnings misses -- execution concerns. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- 2 consecutive earnings misses -- execution concerns — Growth
- RSI at 80 is in overbought territory — Technical